EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Unmet Needs in Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: A Comprehensive Review

Anthony Vignone, Simone Di Cola, Flaminia Ferri, Francesco Covotta, Lewis J. Frey, Wing-Kin Syn, Domenico Alvaro, Vincenzo Cardinale

Livers · 05.08.2026 · 6 (4) · 75

DOI: 10.3390/livers6040075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Livers, online erschienen am 05.08.2026. Verfasst von Anthony Vignone und 7 weiteren Autor:innen. Die Arbeit nennt 258 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary sclerosing cholangitis (PSC) is a rare cholangiopathy strongly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis. PSC-IBD defines a clinically quiescent but biologically aggressive colitis phenotype, characterized by extensive yet often asymptomatic mucosal inflammation and disproportionately elevated risks of colorectal cancer—approximately 3- to 5-fold higher than in IBD alone—and cholangiocarcinoma (CCA), with IBD comorbidity representing an independent risk factor for hepatopancreatobiliary malignancy. The pathogenesis remains incompletely understood but involves genetic susceptibility, immune dysregulation—including aberrant lymphocyte trafficking and an imbalance between T helper 17 (Th17) and regulatory T (Treg) cells—intestinal barrier dysfunction, and gut–liver axis perturbations involving alterations in the microbiota and bile acid homeostasis. Within the biliary tree, chronic inflammation activates peribiliary glands (PBGs), which harbor stem/progenitor cells. PBG hyperplasia may contribute to periductal fibrosis through Hedgehog signaling and epithelial-to-mesenchymal transition and may represent a key step in PSC-associated cholangiocarcinogenesis. The true burden of PSC-IBD is likely underestimated, as PSC may remain clinically silent for years. Bidirectional screening is therefore essential: all patients with PSC should undergo ileocolonoscopy with biopsies regardless of symptoms, whereas patients with IBD and cholestatic liver biochemistry—particularly elevated gamma-glutamyl transferase or alkaline phosphatase—should undergo magnetic resonance cholangiopancreatography. No medical therapy has demonstrated a clear ability to alter the natural history of PSC, and liver transplantation remains the only definitive treatment for advanced disease. This review integrates current evidence on the epidemiology, pathophysiology, and management of PSC-IBD, critically examining unmet needs in timely diagnosis, mechanistic understanding, and therapeutic development, with particular attention to non-invasive biomarkers, microbiota-directed strategies, individualized risk stratification, and disease-modifying endpoints.

Zitieren

APA

Vignone, A., Cola, S. D., Ferri, F., Covotta, F., Frey, L. J., Syn, W., Alvaro, D., & Cardinale, V. (2026). Unmet Needs in Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: A Comprehensive Review. Livers, 6(4), 75. https://doi.org/10.3390/livers6040075

Vancouver

Vignone A, Cola SD, Ferri F, Covotta F, Frey LJ, Syn W, et al. Unmet Needs in Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: A Comprehensive Review. Livers. 2026;6(4):75. doi:10.3390/livers6040075

BibTeX
@article{Vignone2026,
  author = {Vignone, Anthony and Cola, Simone Di and Ferri, Flaminia and Covotta, Francesco and Frey, Lewis J. and Syn, Wing-Kin and Alvaro, Domenico and Cardinale, Vincenzo},
  title = {Unmet Needs in Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: A Comprehensive Review},
  journal = {Livers},
  year = {2026},
  volume = {6},
  number = {4},
  pages = {75},
  doi = {10.3390/livers6040075}
}
Kostenlos starten →